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Nonalcoholic steatohepatitis (NASH) is a disease which is
characterized by hepatic lesions similar to those produced
by alcohol but which appear in subjects who do not con-
sume excessive alcohol. The term NASH was proposed by
Ludwig and cols. in 1980 [1] and covers a wide spectrum of
liver damage including simple steatosis, steatohepatitis with
fatty vacuoles, necroinflammatory changes and/or a vari-
able degree of fibrosis and, lastly, well-established cirrhosis.
Thus, a more correct term would be nonalcoholic fatty liver,
although most authors continue to use the term NASH to de-
nominate this disease. Interest in NASH has increased in re-
cent years and the number of publications related to this dis-
ease has increased exponentially [2-11]. However, many
aspects of the physiopathology, the natural history, and the
treatment of NASH remain to be elucidated.
The prevalence of NASH is not well known and may be
underestimated since a large proportion of the patients are
asymptomatic and present discrete biological alterations,
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Abstract
Nonalcoholic fatty liver disease (NAFLD) is an increasingly
recognized condition whose symptoms and pathology re-
semble those of alcohol-induced liver injury. NAFLD in-
cludes fatty liver, steatohepatitis (NASH) with inflammatory
changes and fibrosis, and cirrhosis. NAFLD is usually seen
in association with obesity, diabetes, hypertension, and hy-
pertriglyceridemia, as the hepatic component of a metabolic
syndrome. Most NAFLD patients are asymptomatic and usu-
ally present with mild elevations in aminotransferases. The
diagnosis should be established by liver biopsy. The natural
history of this disease is not well defined, but progression to
cirrhosis and hepatocellular carcinoma is well recognized in
some patients. The pathogenesis is not well known but the
accumulation of fat in the liver is probably related to insulin
resistance, which leads to altered free fatty acid metabolism.
The progression from NAFLD to NASH and cirrhosis is less
clear but increasing evidence suggests that oxidative stress
may enhance proinflammatory and profibrogenic cytokines
and that this leads to mitochondrial dysfunction followed by
development of inflammation, necrosis, and fibrosis. There
is no established treatment for NASH, and current therapies
are focused on correcting the insulin resistance or reducing
oxidative stress. Although the results of some recent pilot
studies are promising, prospective, randomized studies with
clearly defined histological endpoints are needed.
Resum
El fetge gras no alcohòlic es caracteritza per unes lesions
hepàtiques semblants a les de la malaltia hepàtica alcohòli-
ca, que comprèn des de l’esteatosi simple i l’esteatohepati-
tis amb canvis inflamatoris i fibrosi fins a la cirrosi. És una
malaltia cada vegada més freqüent que s’associa amb l’o-
besitat, la diabetis i la dislipèmia, i és probablement el com-
ponent hepàtic d’una síndrome metabòlica. La seva patogè-
nesi no és ben coneguda, però la resistència a la insulina i
l’augment d’àcids grassos lliures al fetge hi tenen un paper
fonamental, en provocar un estrès oxidatiu i activar els me-
canismes responsables de la inflamació, la necrosi i la fibro-
si. El diagnòstic s’ha de fer mitjançant una biòpsia del fetge,
la qual també permet establir la gravetat de les lesions. A
part del tractament dels factors associats, l’esteatohepatitis
no alcohòlica no té un tractament establert, tot i que s’estan
assajant fàrmacs que milloren la resistència a la insulina i
d’altres amb acció antioxidant. Els resultats d’alguns estudis
pilot són esperançadors, encara que falten estudis contro-
lats, amb grups mes grans de malalts i que valorin els can-
vis histològics.
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and liver biopsy is not performed. The diagnosis of this dis-
ease is, however, very frequent and it is considered that
from 1% to 8% of liver biopsies correspond to NASH [7].
One of the factors thought to influence the rise in the preva-
lence of NASH is the increasing incidence of obesity among
the Western population and which is already manifested
during adolescence. While in the past NASH was consid-
ered to be a disease which fundamentally affected middle-
aged, obese women, many of whom were diabetic, NASH
has currently been found to affect both sexes equally and
may be observed in younger individuals and even adoles-
cents.
Etiology
NASH has been associated with multiple etiological factors
such as congenital or acquired metabolic alterations, nutri-
tional disturbances, surgical procedures, drugs and other
toxic products. Obesity is the most frequently associated fac-
tor and the prevalence of NASH appears to be associated
with the degree of obesity. Thus, in some series from 9% to
26% of obese patients present NASH lesions [12], while the
prevalence may be greater than 60% among patients with
morbid obesity who undergo surgery [13]. On the other hand,
steatosis has been detected in 75% of the obese population
[14]. Type 2 diabetes mellitus is often associated with NASH.
A clear relationship has also been observed between this
process and increased resistance to insulin, even in patients
with normal glucose tolerance [15]. A high percentage of pa-
tients with NASH present dyslipemia, hypercholesterolemia,
hypertriglyceridemia or both. In clinical practice, most pa-
tients with NASH present obesity, type 2 diabetes mellitus or
dyslipemia as the etiologic factor, with the association of sev-
eral of these factors being frequent. Therefore, nonalcoholic
fatty liver is beginning to be considered as the hepatic com-
ponent in a metabolic syndrome characterized by obesity,
hyperinsulinemia, increase in resistance to insulin, diabetes,
hypertriglyceridemia and hypertension [16,17].
To a lesser extent, NASH may be due to other causes. To-
tal parenteral nutrition and a rapid loss of weight may cause
NASH. Some hereditary metabolic diseases such as abetal-
ipoproteinemia, the Weber Christian syndrome, galac-
tosemia, and thyrosinemia are also causes of NASH [6-
8,10]. Jejunoileal bypass for the treatment of morbid obesity
was associated with NASH lesions in more than 40 % of the
patients, with some developing signs of acute hepatic fail-
ure, which led to the abandonment of this procedure [18].
Other surgical procedures such as jejunocolic bypass, bil-
iopancreatic bypass and gastroplasty may also cause
NASH, although with a lower frequency. Many drugs have
also been associated with NASH. Among these, amio-
darone, perhexillin maleate, tamoxifen, estrogens, nifedip-
ine and corticosteroids are of note. The appearance of
NASH has recently been described in workers who are
chronically exposed to petrochemical vapors [19]. In Spain,
NASH has been associated with the toxic oil syndrome with
9% of the patients in the late phase of this syndrome pre-
senting hepatic lesions compatible with NASH [20].
Pathogenesis
In recent years great advances have been made in the
knowledge of the pathogenesis of nonalcoholic fatty liver
and its progression to steatohepatitis, although many points
remain to be elucidated [21-23]. The most prevailing theory
is the “two hit” hypothesis proposed by Day and James in
1998 [24]. The first “hit” is the accumulation of fat in the liver
in the form of fatty acids and triglycerides. This increase in
fat produces oxidative stress, this being the so-called “se-
cond hit”, which makes the hepatocyte vulnerable to apop-
tosis and necrosis (Figure1).
The deposit of fatty acids and triglycerides in the liver is
produced when there is a greater contribution and/or diffi-
culty in the use of these nutrients. Free fatty acids are syn-
thesized in the liver or transported to the liver bound to albu-
min proceeding from the intestinal absorption or lipolysis in
the adipose tissue. Likewise, free fatty acids may accumu-
late in the liver when their oxidation is reduced or when there
is an alteration in triglyceride transport out of the liver in the
form of very low density lipoproteins (VLDL).
The increase in resistance to insulin is very frequent in pa-
tients with nonalcoholic fatty liver and it is believed to be re-
sponsible for most of the changes in lipid metabolism [25-
27]. Insulin is fundamental in energetic regulation at the level
of the skeletal muscle, the adipocytes and hepatocytes. In
muscle, insulin facilitates the enhancement of glucose by the
translocation of the glucose transporter-4 (GLUT-4) from the
cytoplasm to the cell surface [28]. In adipocytes, insulin in-
hibits lipoprotein-lipase, impeding the rupture of the triglyc-
Insulin resistance Associated factors
NAFLD
Genetic factors
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Figure 1. Schematic representation of the pathogenesis of nonalco-
holic steatohepatitis.
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erides and the release of the free fatty acids [29]. In hepato-
cytes, insulin favors glycogenesis and inhibits glycogenoly-
sis and gluconeogenesis [30]. In contrast, insulin resistance
is characterized by an increase in the circulating levels of
free fatty acids due to an increase in lipolysis and a lower ox-
idation both in muscle and in the liver [27]. In addition, the hy-
perinsulinemia associated with insulin resistance decreases
the synthesis of apolipoprotein B-100, which is an essential
component of the VLDL, thus diminishing the transport of the
triglycerides outside the hepatocytes [31,32].
The development of fatty liver may also be influenced
by other mechanisms such as diet [33], genetic factors such
as polymorphisms of the microsomal protein transporter of
the triglycerides [35,36], an increase in the circulating levels
of leptin [36], which has been related to the increase in the
resistance to insulin, and some cytokines such as tumoral
necrosis factor alfa (TNFα) and adiponectin [37]. TNFα lev-
els are increased in patients with fatty liver and enhance in-
sulin resistance [38]. By contrast, the expression of mRNA of
adiponectin is reduced while the administration of
adiponectin to experimental models normalizes insulin resis-
tance and reduces the deposit of triglycerides in the liver
[30]. Likewise, TNFα may inhibit the expression of
adiponectin, thereby contributing to insulin resistance [29].
Some patients only develop steatosis while in others the le-
sions progress to steatohepatitis. Several factors may influ-
ence the different evolution of the patients, although the mech-
anisms remain unclear. In the second stage of the disease, the
increase in the deposit of fatty acids also plays an important
role in disease progression. Mitochondrial ß-oxidation is the
normal metabolic route of free fatty acids. This route is less ef-
fective in NASH due to mitochondrial alterations [39,40] and,
moreover, it is saturated by the excess of fatty acids activating
other routes such as microsomal oxidation, producing overex-
pression of cytochromes P450 2E1 and 3A4 [41,42] and an in-
crease in peroxisomal oxidation [43]. All of this induces the for-
mation of reactive oxygen species, oxidative stress and lipid
peroxidation [39]. The final products of lipid peroxidation, mal-
ondialdehyde and hydroxinonenal stimulate the synthesis of
cytokines and adhesion molecules [44].
The generation of reactive oxygen species saturates the
physiological antioxidant systems. It also induces the synthe-
sis of the nuclear kβ transcription factor, and this in turn stimu-
lates the production of proinflammatory cytokines such as
TNFα and IL-8 and the synthesis of adhesion molecules which
increase neutrophilic chemotaxis [22]. The greater production
of TNFα and other proinflammatory cytokines is also related to
a rise in endotoxin [45] and Kupffer cell dysfunction [46].
The activation of the hepatic stellate cells to initiate the
process of fibrogenesis in NASH depends on several factors
such as free radicals, cytokines, and products derived from
damaged hepatocytes [47-49]. The transforming growth fac-
tor beta (TGFβ) is probably the cytokine with strongest profi-
brogenetic properties [50]. In experimental models, leptin  is
very important in the development of fibrosis [51]. In these
models leptin is produced by activated stellate cells and in-
teracts in a paracrine fashion with Kupffer cell receptors, thus
favoring the production of TGFβ and increasing fibrogenesis
[52,53]. Similarly, patients with NASH and fibrosis present
overexpression of the leptin receptor in hepatic tissue (REF).
The role of the rise in hepatic iron deposits as a coadjuvant
in the pathogenesis of NASH is a matter of debate. Some
studies have shown that a high percentage of patients with
NASH present an increase in ferritin or transferrin saturation
together with a moderate increase in hepatic iron deposits,
although it remains unclear whether these alterations are a
cause or a consequence of liver damage [54]. Indeed, iron
may contribute to the pathogenesis of NASH by several
mechanisms. Experimental studies have demonstrated that
iron stimulates lipid peroxidation and cell damage [55] and
also activates stellate cells, thereby favoring fibrogenesis
[56]. After the demonstration of the rise in ferritin and iron de-
posits in some patients with NASH, a possible association
between this disease and the gene of hemochromatosis was
sought. In a recent study, George et al. [57] found that pa-
tients with NASH showed a prevalence of the Cys 282Tyr mu-
tation of 31 %, and this  situation was accompanied by an in-
crease in iron deposits as well as a higher degree of fibrosis.
In another study, Bonkovsky et al. [58] observed that patients
with NASH and the Cys282Tyr or H6D3 mutations of the he-
mochromatosis gene had higher levels of ferritin and trans-
ferrin saturation as well as increased iron deposits but with
no relationship between hepatic iron concentrations and the
degree of fibrosis. No have more recent studies shown that
hepatic iron concentrations are a predictive factor for the de-
gree of fibrosis in patients with NASH [59]. These discrepan-
cies may be explained by geographical and methodological
differences in the evaluation of the hepatic iron deposits.
However, the most recent results suggest that the role of iron
in the pathogenesis of NASH is small.
In summary, NASH develops in two stages. In the first
stage, steatosis develops as a consequence of the alterations
in lipid metabolism related to an increase in resistance to in-
sulin. In the second stage, inflammatory changes and fibrosis
appear. Oxidative stress plays an essential role in this second
stage and is triggered by the accumulation of fatty acids.
Moreover, in the second stage both lipid peroxidation and
liver damage and fibrosis may be influenced by different fac-
tors such as the induction of CYP2E1, endotoxin, iron, Kupffer
cell dysfunction and changes in mitochondria [60] and ATP
homeostasis [61,62]. Neither the interactions among all these
factors nor the importance of each factor has been well es-
tablished.
Clinical manifestations
Most of the patients with NASH are asymptomatic and in these
patients the diagnosis is usually the result of the casual discov-
ery of hepatomegaly and/or alterations in hepatic biology dur-
ing the course of a health examination or because of consulta-
tion for an extrahepatic disease. In symptomatic cases, the
symptomatology is unspecific, with asthenia, general malaise,
and discomfort on the right side of the upper abdomen. On
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physical exploration, hepatomegaly is the most frequent and,
in general, the only finding. Only patients with cirrhosis may
present cutaneous stigmata and splenomegaly [6-8,10].
Laboratory tests are also unspecific. In most patients there
is a moderate elevation in transaminases and, contrary to
what occurs in alcoholic liver disease, the AST/ALT ratio is
usually less than one. A moderate elevation in alkaline phos-
phatase is also frequent, as is that of gammaglutamyl
transpeptidase. On the other hand, bilirubin, albumin, and the
prothrombin rate are usually normal and are only altered in
patients with cirrhosis. Some patients present low titers of an-
titissular antibodies, especially antinuclear antibodies. De-
pending on the cause of NASH, there is a frequent elevation
of serum lipid (hypercholesterolemia and/or hypertriglyc-
eridemia) and hyperglycemia. Patients with NASH may show
an increase of iron in the liver which is accompanied by an el-
evated saturation of transferrin and serum ferritin. Some au-
thors have also reported a high prevalence of the Cys282Tyr
mutation of the hemochromatosis gene [6-8,10,63].
Ultrasonography is the least expensive and most effective
imaging technique to detect steatosis and also allows a
semiquantitative estimation of the intensity of the disease.
However, the sensitivity of ultrasonography or the remaining
imaging techniques to detect the fibrosis associated with
steatosis is much lower [64]. The liver can be observed as ir-
regular or nodular and extrahepatic signs of portal hyperten-
sion can be seen only in the cirrhotic phase. Axial tomogra-
phy and magnetic resonance have the same limitations as
ultrasonagraphy. Only in the infrequent cases of focal
steatosis can magnetic resonance imaging distinguish
space-occupying lesions from focal fatty infiltration [65]. 
Histologic findings
The spectrum of lesions in NASH is the same as that obser-
ved in alcoholic liver disease, from simple steatosis to cirrho-
sis. The minimum lesions necessary for the diagnosis of
NASH is not yet well established, although most authors
consider that steatosis, lobulillar inflammation, hepatocyte
degeneration or ballooning and/or fibrosis would then be
present. Steatosis is usually macrovacuolar with varying in-
tensity, from slight, only affecting the perivenular region, to
practically massive. In the cirrhotic phase, steatosis may be
minimal. Mallory hyaline bodies are not a requisite for the
diagnosis but are often present. Glycogenic degeneration of
the nuclei may also be observed. Neutrophils predominate
in inflammatory infiltrates, although lymphocytes and ma-
crophages may also be present. Positive staining for iron va-
ries according to the series. Pericellular, perisinudoidal or
periportal fibrosis is found in 40% to 80% of the patients with
NASH. Fibrosis is marked in the pericentral region and ran-
ges from fine septa around the centrolobulillar vein or
around groups of hepatocytes to thick septa and bridges of
fibrosis which distort the hepatic architecture. In some series
from 7% to 16% of the patients with NASH have cirrhosis in
the initial biopsy. In the cirrhosis phase both steatosis and
the inflammatory changes may have disappeared, making
the etiological diagnosis difficult to establish.
A classification has been proposed for nonalcoholic fatty
liver according to the histologic lesions [66]. Steatosis is
classified into 3 grades according to hepatocyte involve-
ment: 33 %, from 33 % to 66 % or more than 66 % of the he-
patocytes, respectively. In regard to steatohepatitis, a scor-
ing system has been proposed which establishes the
activity according to the intensity of liver damage and inflam-
mation as the stage according to the degree of fibrosis.
Grade 1 or mild steatohepatitis presents steatosis, occa-
sional hepatocyte ballooning, and mild lobulillar or portal in-
flammation. Grade 2 or moderate steatohepatitis is charac-
terized by more marked steatosis, evident ballooning, and
more intense inflammatory infiltrates than those observed in
grade 1. Grade 3 or intense steatohepatitis presents impor-
tant steatosis, and both lobulillar and portal ballooning and
inflammation. Stage 1 fibrosis includes perisinusoidal, espe-
cially centrolobulillar, fibrosis. Stage 2 fibrosis is perisi-
nosoidal and portal and stage 3 is similar to stage 2 plus fi-
brotic bridges and stage 4, cirrhosis (table 1).
Diagnosis
Although NASH may be suspected on the basis of the clini-
cal manifestations, laboratory data, and complementary ex-
plorations, the diagnosis of this disease should be based on
liver biopsy. In all cases, liver disease of another etiology
should be excluded. Thus, apart from liver function tests, vi-
ral markers, antitissular antibodies, ferritin, cupremia, cupru-
ria and ceruloplasmin, and alpha-1-antitrypsin should be
studied. Ultrasonography is the most indicated imaging test
Table 1. Histological classification of NASH
Fatty liver
Grade 1 (mild): <33% of hepatocytes
Grade 2 (moderate): 33%-66% of hepatocytes
Grade 3 (severe): >66% of hepatocytes
Steatohepatitis
Necroinflammatory grade
Grade 1 (mild): steatosis <66% of hepatocytes, occasional
ballooned zone 3 hepatocytes, mild intra-acinar
inflammation and polymorphonuclear infiltration,
and mild or absent portal inflammation.
Grade 2 (moderate): Steatosis of any degree, ballooning of
hepatocytes patent, mild or moderate
intra-acinar and portal inflammation.
Grade 3 (severe): steatosis, diffuse ballooning of hepatocytes,
inflammation and polimorphonuclear
infiltration in zone 3, and mild or moderate
portal inflammation.
Fibrosis 
Stage 1: Zone 3 perisinusoidal/pericellular fibrosis.
Stage 2: Zone 3 perisinusoidal/pericellular fibrosis with focal or
extensive periportal fibrosis.
Stage 3: Zone 3 perisinusoidal/pericellular fibrosis and portal
fibrosis with bridging fibrosis.
Stage 4: Cirrhosis.
435-498 Contributions Vol. 2-4  11/05/05  09:29  Página 458
Non alcoholic steatohepatitis 459
due to its relatively low cost and easy applicability. As pre-
viously mentioned, it is sensitive enough to detect steatosis
but much less sensitive for the detection of associated fibro-
sis. Steatosis may also be observed by axial tomography or
magnetic resonance imaging techniques [10,67].
Excessive alcohol intake should also be carefully ruled
out. To do this the patients and their relatives should be in-
terviewed, and laboratory tests should be evaluated since
an elevated mean corpuscular erythrocyte volume or an
AST/ALT ratio greater than one may be orientative [68-70].
When in doubt, more specific tests such as serial alcohol de-
terminations in urine or the determination of markers such as
carbohydrate deficient transferrin may be useful [71-73]. Al-
though the limits of alcohol intake are not well established,
alcohol ingestion of up to 20 g/day may be considered as
not being responsible for the disease in these patients.
The need for performing a liver biopsy to confirm the suspi-
cion of nonalcoholic steatohepatitis is still under debate [9,74].
This is because the patients are, generally, asymptomatic, the
prognosis is good in many cases, the treatment of these pa-
tients is not well established, and biopsy is an expensive tech-
nique which carries a risk which should be taken into account.
For all these reasons, many authors consider that from a prac-
tical point of view the establishment of the diagnosis of suspi-
cion and periodic monitoring of the patient are sufficient.
The  liver biopsy is not limited to confirming the diagnosis,
it also allows pure steatosis to be distinguished from steato-
hepatitis and classification of the patients according to the
intensity of the hepatic lesions [66]. This is important since a
high percentage of patients already have intense fibrosis on
the initial biopsy, and a recent study has shown that in pa-
tients with normal transaminases the whole spectrum of le-
sions may be observed, including advanced fibrosis [75].
The possibility of determining the intensity of the lesions al-
lows the prognosis of the patients to be established. Like-
wise, due to the heterogeneity of the patients, a liver biopsy
is necessary for the inclusion of a patient in a therapeutic
study to allow correct interpretation of the results. Patients
with the diagnosis of suspicion of NASH should be informed
of the need for a liver biopsy to confirm the diagnosis. They
should be told of the advantages and inconveniences of car-
rying out a biopsy in this disease and they should actively
participate in the decision to undertake this exploration.
Prognosis
Knowledge of the natural history of NASH is not precise since
few studies with a long-term follow-up and histologic control
have been performed in these patients. Simple steatosis has
a good prognosis. A series of 40 patients was followed over a
mean of 11 years with no observed progression of the lesions
in any of the patients [76]. In another series of 49 patients
with simple steatosis, only one died due to liver-related cau-
ses [77]. Despite the similarity of the lesions and their patho-
genesis, NASH has better prognosis than alcoholic hepatitis,
although the lesions may also progress to cirrhosis and even
hepatocarcinoma. In a review of 3 series with a total of 28 pa-
tients with a long term histologic follow-up, the lesions remai-
ned unmodified in 54 % of the patients, the fibrosis progres-
sed in 43 %, and only one patient showed improvement [55].
All the studies coincide in concluding that age, obesity and
diabetes are factors of poor prognosis [13, 78-80]. In a re-
cent series including 22 patients with NASH with a control
biopsy, progression of fibrosis was observed in one third of
the patients, and in one third of these patients the progres-
sion from mild to advanced fibrosis was rapid [81].
There is increasing evidence that NASH is one of the ma-
jor precursors of cryptogenetic cirrhosis. Recent studies
have shown that 70% of the patients with cryptogenetic cir-
rhosis over the age of 60 years have a history of obesity,
type 2 diabetes mellitus or dyslipemia suggesting NASH as
the cause of cirrhosis [82,83]. In this phase the steatosis and
other lesions characteristic of NASH are mild or even absent
in the liver biopsy. Recent evidence also suggests that some
patients with NASH that progresses to cirrhosis will develop
hepatocellular carcinoma [84-86].
Treatment
At present there is no specific treatment for NASH. The cur-
rent treatment consists of a series of general measures
such as the abstinence from alcohol, a balanced diet, mode-
rate physical exercise, and the avoidance of drugs and ex-
posure to environmental toxins which may potentially cause
the disease. Likewise, the etiological factor should be trea-
ted. Thanks to a better knowledge of the pathogenesis of
NASH, a series of pharmacological treatments has been
proposed. However,  to date the experience with these
drugs has been limited. In patients with advanced cirrhosis,
as in those with cirrhosis of another etiology, liver transplan-
tation is also indicated [10] (table 2).
Table 2. Treatment of non alcoholic steatohepatitis
1. Treatment of associated disorders
– Gradual weight loss
– Control of diabetes
– Control of dyslipidemia
2. Potential pharmacological approaches
Improved insulin resistance
– Metformin
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Treatment of the etiological factor
The treatment of obesity has been shown to be effective in
both adolescents and adults. In most cases, progressive
weight loss together with the treatment of diabetes and/or
dyslipemia, when associated with obesity, is accompanied
by an improvement in analytical alterations and ultrasono-
graphic changes [87]. The method of achieving weight loss
is important and should be progressive, with physical exer-
cise and a balanced diet. Rapid weight loss with a very strict
diet is counterproductive since mobilization of fatty acids in
the adipose tissue of the liver may be produced which may
deprive the patient of the correct metabolism of proteins and
other essential nutrients, all of which produce steatosis and
worsening of the lesions [89]. On many occasions it is diffi-
cult to ensure that the patients maintain the weight loss, and
they recover the weight within a few months with the conse-
quent reappearance of the lesions. Orlistat is a reversible in-
hibitor of gastric and pancreatic lipases which is beginning
to be used with good results in the treatment of obesity. Re-
cent pilot studies have shown that treatment with orlistat in
patients with NASH can improve liver function tests, steato-
sis, inflammation and fibrosis [90]. Nonetheless, it is doubtful
whether only weight loss is effective in cases with marked fi-
brosis.
In patients with intestinal bypass for the treatment of obe-
sity, the restoration of normal transit and the administration
of metronidazole to reduce endotoxin levels have been
shown to improve the lesions. When the disease appears
during the course of parenteral nutrition, the composition of
this treatment should be modified by increasing lipid contri-
bution in the place of glucose, and choline supplementation
should be provided [91]. Glucose stimulates insulin secre-
tion, which in turn inhibits mitochondrial oxidation of fatty
acids and increases their hepatic synthesis. Choline is nec-
essary for the synthesis of lecitin which, in turn, is necessary
for the formation of VLDL lipoproteins.
Pharmacological treatment
The slight clinical expressiveness of most of the patients and
the belief that the course of the disease is, in general, be-
nign, explain why few therapeutic studies on treatment effi-
cacy with an evaluation according to the histologic changes
have been carried out. Moreover, the studies performed to
date have been pilot studies, most of them uncontrolled and
with a small number of patients. Therefore, there is no esta-
blished treatment for NASH. The potential therapeutic strate-
gies may be divided into three groups according to their me-
chanism of action: drugs which improve the resistance to
insulin, hypolipemic drugs and drugs with an antioxidant
and/or hepatoprotective effect [10,11,21,22].
Among the drugs which improve resistance to insulin,
biguanides such as metformin and thiazolidindiones have
been studied. In experimental models, metformin has been
shown to improve steatosis and inflammation [92]. In pa-
tients with NASH, metformin reduces AST values, although
possible histologic changes have not been evaluated [93].
Troglitazone was the first thiazolidindione tested and also
showed an improvement in transaminases in a small group
of patients [94]. Cases of severe hepatitis have recently
been reported in patients treated with troglitazone and this
drug has therefore been withdrawn [95]. Recently, the first
results of a study on treatment with pioglitazone and rosigli-
tazone have been published. In 26 patients treated for 48
weeks with 4 mg of rosiglitazone every 12 hours, improve-
ment was observed in the resistance to insulin, ALT values,
and histologic lesions, especially inflammation and necro-
sis, although the ALT values returned to the basal levels 6
months after discontinuation of treatment [96]. One pilot
study including 18 patients treated for 48 weeks with 30
mg/day of pioglitazone demonstrated similar results, that is,
an improvement in resistance to insulin, transaminases and
histologic lesions [97]. Both rosiglitazone and pioglitazone
were, in general, well tolerated, with the most frequent ad-
verse event being a significant increase in weight. These
promising results should be confirmed in controlled studies.
In relation to hypolipemic drugs, one controlled study did
not show any beneficial effect with treatment with clofibrate
[98]. Two controlled studies with a small number of patients
demonstrated a significant improvement in transaminases
with gemfibrozyl [99] and probucol [100], respectively. His-
tologic changes were not evaluated in any of these studies.
Atorvastatin was also evaluated in a pilot study in seven pa-
tients and showed a decrease in plasmatic lipid values as
well as an improvement in steatosis, inflammation and fibro-
sis in the biopsy carried out after one year of treatment [101].
The administration of vitamin E at a dose of 400 to 1200
mg/day achieved an improvement in transaminases in a
group of adolescents with steatohepatitis [102]. The admin-
istration of tocoferol alone or combined with ascorbic acid
showed relatively small changes in the histologic lesions in
adults [103,104]. Likewise, in another pilot study, the admin-
istration of vitamin E did not produce modifications in the lev-
els of the cytokines involved in the pathogenesis of NASH
(105). 
In still another pilot study, one year of treatment with ur-
sodeoxycholic acid at a dose of 13 to 15 mg/day achieved
an improvement in both the biochemical parameters and the
degree of steatosis in the liver biopsy [98]. However, the
same authors have recently published the results of a con-
trolled, double-blind study including 166 patients treated
with the same dose of ursodeoxycholic acid for two years.
Pre– and post-treatment biopsies were evaluated in 107 pa-
tients and showed the same changes in the group treated
with the drugs and in the placebo group [106]. Thus, al-
though well tolerated, from this study it may be deduced that
ursodeoxycholic acid is not effective in the treatment of
NASH.
Treatment with betaine, a precursor of s-adenosylmethio-
nine, a drug with hepatoprotective effects, has been evaluat-
ed in a pilot study including 10 patients. After one year of
treatment all the patients showed normalization or improve-
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ment in transaminase values as well as improvement in the
steatosis, the necroinflammatory lesions and the degree of
fibrosis [107]. These results should be confirmed with con-
trolled studies. Other drugs with antioxidant effects such as
s-adenosylmethionine or metadoxin have not been evaluat-
ed in NASH.
In conclusion, controlled studies including a sufficient
number of patients are required with the main objective be-
ing the histologic changes to evaluate correctly the different
therapies proposed. Likewise, studies should perhaps also
be designed to evaluate the effects of the combination of dif-
ferent therapeutic approaches [108].
Liver transplantation
Liver transplantation is a therapeutic option which should be
considered in patients with NASH in an advanced phase,
although in some cases morbid obesity or the complications
of diabetes mellitus may contraindicate this procedure. The
immediate results of transplantation in these patients are
good [109], although the lesions of steatohepatitis may re-
appear in the mid-term [110,111]. The cause of the recurren-
ce of lesions is unknown but may be due to the persistence
of an etiological factor such as prolonged treatment with cor-
ticosteroids. Cyclosporine administration may also cause
mitochondrial damage.
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